The companies are joining their respective technologies to create an end-to-end genomic data analysis solution.
The firm raised its full fiscal year 2018 revenue and adjusted earnings per share guidance.
Agilent said the acquisition will enable it to provide consumers with a single informatics solution across laboratory and operational domains.
Three vendors applied their variant calling and interpretation pipelines to the same tumor NGS panel data and came up with overlapping but different results.
The firm reported $52.8 million in revenues, up from $26.3 million during the same period last year and beat the average Wall Street revenue estimate of $44.9 million.
Although revenues from the firm's global diagnostics business were down 6 percent year over year, molecular diagnostic product revenues were up 6 percent.
The company reported first quarter revenues of $19.4 million, missing Wall Street's estimate of $24.5 million.
On an adjusted basis and at constant exchange rates, Q1 revenues grew 6 percent year over year, led by 9 percent growth in molecular diagnostics.
Test volume and revenues increased in the US, especially in prostate cancer. Meanwhile, international test volume was down but corresponding revenue increased.
The deal expands Evotec's existing CRISPR licenses through the Broad Institute and adds to ERS's list of licensees for its gene editing technology.
The test, which received FDA clearance in late 2017, runs in as little as 18 minutes.
The offer put a value of 181 pence per share on Horizon's stock, representing a premium of approximately 26 percent to Horizon's closing share price on May 1.
The company recognized $20 million in Q1 revenues and grew its testing volume by 18 percent.
In 2018, the company expects to place between 140 and 170 new ePlex analyzers, and an annuity per ePlex in the $100,000 to $120,000 range.
Positive first quarter earnings reports lifted many stocks of life science tools firms even as the broader biotechnology market suffered.
A team of European researchers analyzed DNA from infected medieval skeletons to find the HLA allele DRB1*15:01 was more common among leprosy patients.
Ahead of the national launch, 44,000 early participants signed up for the program during a beta phase, and 26,000 people have completed the enrollment process.
The lab is located within Novogene's sequencing center at the Sacramento campus of the University of California, Davis.
The company said it also saw record cash collections in the quarter despite challenges caused by regulatory change.
The coverage decisions follow similar decisions by Blue Shield of California and First Coast Service Options last year.
The company announced agreements to use the Oncomine Dx Target Test in drug development programs with Daiichi Sankyo, Takeda, and Spectrum Pharmaceuticals.
The partners' first project will involve using Cellectis' TALEN gene editing technology to create virus-resistant human cells.
The deal marks the latest in a series of acquisition LGC has made in recent years to expand its presence on the nucleic acid chemistry market.
The Hartwig Medical Foundation currently sequences about 7.5 percent of all metastatic cancer biopsies in the Netherlands, processing 250 to 300 samples per month.
The company said revenues in its diagnostics business unit rose 62 percent during the quarter.
US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.
A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.
The New York Times writes about the appearance of mosaicism in healthy people.
In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.